// App-Quantinova.ai

7501.0 : Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

Researchers

Presenter

  • Courtney Denton Dinardo

Principal Investigators

  • Andre C. Schuh

  • Eytan M. Stein

  • Pau Montesinos

  • Andrew Wei

  • Stephane De Botton

  • Amer Methqal Zeidan

  • Amir Tahmasb Fathi

  • Lynn Quek

  • Hagop M. Kantarjian

  • Mark G. Frattini

  • Frederik Lersch

  • Jing Gong

  • Aleksandra Franovic

  • Paresh Vyas

  • Hartmut Dohner

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Gustave Roussy, Villejuif, France

  • Yale University School of Medicine, New Haven, CT

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • Oxford Medical Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • Bristol-Myers Squibb, Summit, NJ

  • MRC Molecular Haematology Unit and Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals, Oxford, United Kingdom

  • Universitatsklinikum Ulm, Ulm, Germany

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

  • Enasidenib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02677922

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved